ArticleArthritis research & therapy2026
Interferon α-induced HERC6 provokes podocyte dysfunction via mitotic catastrophe in lupus nephritis.
Article in Arthritis research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundHECT and RLD Domain Containing E3 Ubiquitin Protein Ligase Family Member 6 (HERC6) is an IFN-stimulated gene (ISG) encoding an E3 ubiquitin ligase that plays significant roles in antiviral innate immunity. However, current research on HERC6 has primarily focused on the liver and immune cells. Its expression, regulation, and function in the kidney, particularly in podocytes remain largely unexplored. The aim of this study is to investigate the pathogenic role and mechanism of the E3 ubiquitin ligase HERC6 in podocyte injury of lupus nephritis (LN).
methodsKey genes were identified through bioinformatic screening of LN patient datasets. HERC6 expression was validated in renal tissues from LN patients and two lupus murine models, and the correlation between its urinary HERC6 levels and the clinical parameters of patients was analyzed. In vivo, the therapeutic efficacy of renal HERC6 knockdown was evaluated in MRL/lpr mice using AAV9-mediated delivery of HERC6-specific shRNA.In vitro, podocytes were stimulated with IFN-α to investigate gene induction. Following HERC6 knockdown, cellular phenotypes, inflammatory cytokine secretion, apoptosis, cell cycle, and mitotic spindle morphology were analyzed using qPCR, western blot, flow cytometry, ELISA, and immunofluorescence.
resultsBioinformatic analysis identified HERC6 as a key differentially expressed gene in LN. Its significant upregulation was validated in renal tissues especially in glomerulus from LN patients and two murine lupus models. Moreover, clinical specimen analysis verified significantly elevated urinary HERC6 levels in LN patients, which correlated tightly with disease activity indicators, including proteinuria and hypocomplementemia. Renal-targeted HERC6 knockdown significantly attenuated lupus nephritis progression in MRL/lpr mice, alleviated both LN progression and podocyte injury. Mechanistically, type I interferon (IFN-α) directly induced HERC6 expression in podocytes. Functional experiments demonstrated that HERC6 knockdown markedly alleviated IFN-α-induced podocyte injury, characterized by restoring expression of podocyte markers, reducing secretion of inflammatory cytokines and decreasing apoptosis. Further investigation revealed that HERC6 deficiency reversed IFN-α-induced mitotic spindle abnormalities and G2/M phase arrest.
conclusionThis study unveiled a novel pathway wherein HERC6 induced podocyte injury through disruption of mitotic homeostasis, revealed its potential as a therapeutic target in LN.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.